Beste Hepatology podcasts (2024)

1
Peter De Cruz on the PREDICT-UC trial of intensified versus standard dose infliximab for steroid-refractory acute severe ulcerative colitis 14:42

23d ago14:42

14:42

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00200-0?dgcid=buzzsprout_icw_podcast_generic_langas Continue this co…

1
In conversation with... Peter De Cruz 14:42

24d ago14:42

14:42

Peter De Cruz (University of Melbourne) discusses the PREDICT-UC trial of intensified versus standard dose infliximab induction therapy for steroid-refractory acute severe ulcerative colitis.Door The Lancet

1
Shahida Din and Beatriz Gros on the harms associated with receiving placebo in trials of drugs for inflammatory bowel disease 34:15

28d ago34:15

34:15

Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease. Read the full articles: https://www.thelancet.com/journals/…

1
In conversation with... Shahida Din and Beatriz Gros 34:15

29d ago34:15

34:15

Shahida Din (Western General Hospital, Edinburgh) and Beatriz Gros (Reina Sofía University Hospital, Cordoba) discuss two new papers on the harms associated with receiving placebo in induction and maintenance trials of biological therapies and small molecules in inflammatory bowel disease.Door The Lancet

1
In conversation with... Arndt Vogel 18:31

4M ago18:31

18:31

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies.Door The Lancet

1
Arndt Vogel on the NALIRICC trial of nanoliposomal irinotecan in pretreated advanced biliary tract cancer 18:23

4M ago18:23

18:23

Arndt Vogel (Toronto General Hospital) discusses the NALIRICC trial of nanoliposomal irinotecan added to fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00119-5?dgc…

1
In conversation with... Nancy Baxter 25:05

5M ago25:05

25:05

Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy.Door The Lancet

1
Nancy Baxter on the duration of colorectal cancer risk reduction with a complete colonoscopy 25:05

5M ago25:05

25:05

Nancy Baxter (University of Melbourne) discusses a population-based study on the duration of risk reduction in colorectal cancer incidence and mortality after a complete colonoscopy. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00084-0?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversatio…

1
In conversation with... Sanna Nybacka and Magnus Simrén 23:16

7M ago23:16

23:16

Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS.Door The Lancet

1
Sanna Nybacka and Magnus Simrén on a trial of low FODMAP diets versus low carbohydrate diets in IBS 23:16

7M ago23:16

23:16

Sanna Nybacka and Magnus Simrén (University of Gothenburg) discuss the CARIBS randomised controlled trial of a low FODMAP diet versus a low-carbohydrate diet versus pharmacological treatment in IBS. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00045-1/fulltext?dgcid=buzzsprout_tlv_podcast_generic_langas …

1
In conversation with... Nuru Noor 19:55

7M ago19:55

19:55

Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease.Door The Lancet

1
Nuru Noor on the PROFILE trial of biomarker-stratified treatment in newly diagnosed Crohn's disease 19:55

7M ago19:55

19:55

Nuru Noor (University of Cambridge) discusses the PROFILE trial of biomarker-stratified treatment strategies in people with newly diagnosed Crohn's disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(24)00034-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Foll…

1
In conversation with... Yusuke Shimakawa 20:54

7M ago20:54

20:54

Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa.Door The Lancet

1
Yusuke Shimakawa on a simple score for hepatitis B treatment eligibility in Africa 20:54

7M ago20:54

20:54

Yusuke Shimakawa (Institut Pasteur) discusses the development and evaluation of a simple score for hepatitis B treatment eligibility in Africa. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00449-1?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on social! Follow us today at... http…

1
Mads Israelsen on validating the new steatotic liver disease nomenclature in people with excessive alcohol intake 16:39

9M ago16:39

16:39

Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00443-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this convers…

1
In conversation with... Mads Israelsen 16:39

9M ago16:39

16:39

Mads Israelsen (Odense University Hospital) discusses a study to validate the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake.Door The Lancet

1
Louise Dye on the role of expectancy and gluten in non-coeliac gluten sensitivity 23:19

9M ago23:19

23:19

Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00317-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversation on socia…

1
In conversation with... Louise Dye 23:19

9M ago23:19

23:19

Louise Dye (University of Leeds) discusses a trial exploring the role of expectancy and gluten ingestion on symptoms in people with non-coeliac gluten sensitivity.Door The Lancet

1
In conversation with... Tzu-Chan Hong 14:40

12M ago14:40

14:40

Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region.Door The Lancet

1
Tzu-Chan Hong on the primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region 14:40

12M ago14:40

14:40

Tzu-Chan Hong (National Taiwan University Cancer Centre) discusses a systematic review and meta-analysis on primary antibiotic resistance of Helicobacter pylori between 1990 and 2022 in the Asia-Pacific region. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00281-9/fulltext?dgcid=buzzsprout_icw_podcast_gen…

1
Sarah Moen on metachronous colorectal cancer risk according to Lynch syndrome pathogenic variant after colectomy 14:45

1y ago14:45

14:45

Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00228-5/fulltext?dgcid=…

1
In conversation with... Sarah Moen 14:45

1y ago14:45

14:45

Sarah Moen (Erasmus University Medical Center) discusses a retrospective cohort study examining the risk of metachronous colorectal cancer after partial or extensive colectomy in carriers of different pathogenic Lynch syndrome variants.Door The Lancet

1
In conversation with... Anna Emilie Kann 16:19

1y ago16:19

16:19

Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease.Door The Lancet

1
Anna Emilie Kann on the causes of mortality in patients with alcohol-related liver disease 16:19

1y ago16:19

16:19

Anna Emilie Kann (Zealand University Hospital, Denmark) discusses a population-based study done in Denmark exploring the causes of mortality in patients with alcohol-related liver disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00192-9/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue t…

1
Robert Krouse on surgical versus non-surgical management of malignant bowel obstruction 16:31

1y ago16:31

16:31

Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00191-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this conversati…

1
In conversation with... Robert Krouse 16:31

1y ago16:31

16:31

Robert Krouse (University of Pennsylvania) discusses the pragmatic S1316 trial of surgical versus non-surgical management for patients with malignant small bowel obstruction.Door The Lancet

1
Marc Rothenberg on a trial of benralizumab in eosinophilic gastritis 14:29

1+ y ago14:29

14:29

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases. Read the full article: https://www.thelancet.com/journals/langas/art…

1
In conversation with... Marc Rothenberg 14:29

1+ y ago14:29

14:29

Marc Rothenberg (University of Cincinnati College of Medicine) discusses a new trial assessing the efficacy and safety of benralizumab in patients with eosinophilic gastritis, and how the surprising findings might change our understanding of eosinophilic gastrointestinal diseases.Door The Lancet

1
In conversation with... Michael Pavlides 17:41

1+ y ago17:41

17:41

Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease.Door The Lancet

1
Michael Pavlides on non-invasive tests for predicting clinical outcomes in non-alcoholic fatty liver disease 17:41

1+ y ago17:41

17:41

Michael Pavlides (University of Oxford) discusses work by the LITMUS Consortium on the prognostic performance of non-invasive tests in patients with non-alcoholic fatty liver disease. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00017-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_langas Continue this c…

1
Jasmohan Bajaj on global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis 12:48

1+ y ago12:48

12:48

Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis. Read the full article: https://www.…

1
In conversation with... Jasmohan Bajaj 12:48

1+ y ago12:48

12:48

Jasmohan Bajaj (Virginia Commonwealth University and Central Virginia Veterans Healthcare System, Richmond, VA, USA), on behalf of the CLEARED Consortium, discusses a prospective observational cohort study examining global disparities in mortality and liver transplantation in hospitalised patients with cirrhosis.…

1
In conversation with... Adelina Artenie 17:15

1+ y ago17:15

17:15

Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender.Door The Lancet

1
Adelina Artenie on the incidence of HIV and HCV in people who inject drugs 17:15

1+ y ago17:15

17:15

Adelina Artenie (University of Bristol, UK) discusses a systematic review and meta-analysis exploring the incidence of HIV and HCV among people who inject drugs, and associations with age and sex or gender. Read the full article: https://www.thelancet.com/journals/langas/article/PIIS2468-1253(23)00018-3/fulltext?dgcid=buzzsprout_icw_podcast_langas_…

1
In conversation with... Johan Burisch 20:00

1+ y ago20:00

20:00

Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings.Door The Lancet

1
Johan Burisch on the costs of inflammatory bowel disease in high-income settings 20:00

1+ y ago20:00

20:00

Johan Burisch (Copenhagen University Hospital, Denmark) discusses the findings and recommendations of The Lancet Gastroenterology & Hepatology Commission on the cost of inflammatory bowel disease in high-income settings. Read the Commission here: The cost of inflammatory bowel disease in high-income settings Continue this conversation on social! Fo…

1
In conversation with... Edouard Louis 21:30

2y ago21:30

21:30

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease.Door The Lancet

1
Edouard Louis on the SPARE trial of infliximab or immunosuppressant withdrawal in Crohn’s disease 21:30

2y ago21:30

21:30

Edouard Louis (University Hospital CHU of Liège) discusses the SPARE randomised controlled trial of infliximab or concomitant immunosuppressant withdrawal in patients with Crohn’s disease. Read the full article: Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE) Continue…

1
In conversation with... Paula Ghaneh 20:20

2y ago20:20

20:20

Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma.Door The Lancet

1
Paula Ghaneh on the ESPAC5 trial of neoadjuvant therapy in borderline resectable pancreatic cancer 20:20

2y ago20:20

20:20

Paula Ghaneh (University of Liverpool) discusses the ESPAC5 randomised controlled trial of short-course neoadjuvant therapy compared with immediate surgery for patients with borderline resectable pancreatic ductal adenocarcinoma. Read the full article: Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINO…

1
In conversation with... Dan Turner 14:51

2y ago14:51

14:51

Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD.Door The Lancet

1
Dan Turner on vedolizumab in children with IBD 14:51

2y ago14:51

14:51

Dan Turner (Shaare Zedek Medical Center) discusses the VEDOKIDS study on the safety, effectiveness, and dosing of vedolizumab in children with IBD. Read the full article: Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS) Continue this conversation on social! Follow us today at... https:…

1
In conversation with... Simon Baunwall 15:21

2y ago15:21

15:21

Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection.Door The Lancet

1
Simon Baunwall on faecal microbiota transplantation for first or second Clostridioides difficile infection 15:21

2y ago15:21

15:21

Simon Baunwall (Aarhus University Hospital) discusses the EarlyFMT trial, a randomized placebo-controlled trial of faecal microbiota transplantation for first or second Clostridioides difficile infection. Read the full article: Faecal microbiota transplantation for first or second Clostridioides difficile infection (EarlyFMT) Continue this conversa…

1
In conversation with... James Alexander 13:48

2y ago13:48

13:48

James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease.Door The Lancet

1
James Alexander on immune responses to COVID-19 vaccination in patients with IBD 13:48

2y ago13:48

13:48

James Alexander (Imperial College London) discusses the latest findings from the VIP case-control study, which is investigating COVID-19 vaccine immune responses in immunosuppressed patients with inflammatory bowel disease. Read the full article: COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory b…

1
Filip Knop on liraglutide for bile acid diarrhoea 15:02

2y ago15:02

15:02

Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea.Door The Lancet

1
Filip Knop on liraglutide for bile acid diarrhoea 15:02

2y ago15:02

15:02

Filip Knop (University of Copenhagen) discusses a trial of liraglutide versus colesevelam for the treatment of bile acid diarrhoea. Read the full article: Safety and efficacy of liraglutide versus colesevelam for the treatment of bile acid diarrhoea: a randomised, double-blind, active-comparator, non-inferiority clinical trial Continue this convers…

1
In conversation with... Edward Kim 14:06

2+ y ago14:06

14:06

Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma.Door The Lancet

1
Edward Kim on radiation segmentectomy for unresectable very early to early stage hepatocellular carcinoma 14:06

2+ y ago14:06

14:06

Edward Kim (Icahn School of Medicine at Mount Sinai) discusses the single-arm RASER study of radiation segmentectomy for patients with unresectable very early to early stage hepatocellular carcinoma. Read the full article: Radiation segmentectomy for curative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): a singl…

Podcasts die het beluisteren waard zijn

Hepatology Podcasts

Podcasts die het beluisteren waard zijn

Korte handleiding